Vivo Capital Fund IX, L.P. 4
4 · Instil Bio, Inc. · Filed Mar 25, 2021
Insider Transaction Report
Form 4
Vivo Capital IX, LLC
10% Owner
Transactions
- Conversion
Series C Preferred Stock
2021-03-23−397,576→ 0 total→ Common Stock (477,091 underlying) - Purchase
Common Stock
2021-03-23$20.00/sh+300,000$6,000,000→ 12,486,787 total - Conversion
Series B Preferred Stock
2021-03-23−9,758,080→ 0 total→ Common Stock (11,709,696 underlying) - Conversion
Common Stock
2021-03-23+477,091→ 12,186,787 total - Conversion
Common Stock
2021-03-23+11,709,696→ 11,709,696 total
Footnotes (2)
- [F1]Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1.2 for one basis, and had no expiration date.
- [F2]The securities are held by Vivo Capital Fund IX, L.P. ("Fund IX"). Vivo Capital IX, LLC ("Capital IX") is the general partner of Fund IX. As the managing members of Capital IX, Frank Kung, Edgar Engleman, Shan Fu, Hongbo Lu, Mahendra Shah, Jack Nielsen and Michael Chang share voting and dispositive power over the shares held by Fund IX, but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.